Literature DB >> 20107156

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

José Luis Piñana1, Rodrigo Martino, Jorge Gayoso, Anna Sureda, Javier de la Serna, Jose Luis Díez-Martín, Lourdes Vazquez, Reyes Arranz, José Francisco Tomás, Antonia Sampol, Carlos Solano, Julio Delgado, Jorge Sierra, Dolores Caballero.   

Abstract

BACKGROUND: Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. DESIGN AND METHODS: The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen within prospective trials. The prospective multicenter studies considered included 37 patients with follicular lymphoma who underwent allogeneic stem cell transplantation between 1998 and 2007 with a fludarabine plus melphalan-based reduced intensity conditioning regimen.
RESULTS: The median age of the patients was 50 years (range, 34-62 years) and the median follow-up was 52 months (range, 0.6 to 113 months). Most patients (77%) had stage III-IV at diagnosis, and patients had received a median of three lines of therapy before the reduced intensity conditioning allogeneic stem cell transplantation. At the time of transplantation, 14 patients were in complete remission, 16 in partial remission and 7 had refractory or progressive disease after salvage chemotherapy. The 4-year overall survival rates for patients in complete remission, partial remission, or with refractory or progressive disease were 71%, 48% and 29%, respectively (P=0.09), whereas the 4-year cumulative incidences of non-relapse mortality were 26% (95% CI, 11-61), 33% (95% CI, 16-68) and 71% (95% CI, 44-100), respectively. The incidence of relapse for the whole group was only 8% (95% CI, 2-23).
CONCLUSIONS: We conclude that this strategy of reduced intensity conditioning allogeneic stem cell transplantation may be associated with significant non-relapse mortality in heavily pre-treated patients with follicular lymphoma, but a remarkably low relapse rate. Long-term survival is likely in patients without progressive or refractory disease at the time of transplantation.

Entities:  

Mesh:

Year:  2010        PMID: 20107156      PMCID: PMC2895043          DOI: 10.3324/haematol.2009.017608

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).

Authors:  M T Voso; S Martin; S Hohaus; A Abdallah; R F Schlenk; A D Ho; R Haas
Journal:  Bone Marrow Transplant       Date:  2000-05       Impact factor: 5.483

Review 3.  Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis.

Authors:  J P Klein; J D Rizzo; M J Zhang; N Keiding
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

Review 4.  Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes.

Authors:  Mohammed Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

5.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors:  I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

6.  Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.

Authors:  R Martino; M D Caballero; C Canals; J A Simón; C Solano; A Urbano-Ispízua; J Bargay; C Rayón; A Léon; J Sarrá; J Odriozola; J G Conde; J Sierra; J San Miguel
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

7.  Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Authors:  Stéphane Vigouroux; Mauricette Michallet; Raphaël Porcher; Michel Attal; Lionel Ades; Marc Bernard; Didier Blaise; Reza Tabrizi; Frédéric Garban; Jill-Patrice Cassuto; Patrice Chevalier; Thierry Facon; Norbert Ifrah; Marc Renaud; Hervé Tilly; Jean-Paul Vernant; Mathieu Kuentz; Jean-Henri Bourhis; Pierre Bordigoni; Eric Deconinck; Bruno Lioure; Gérard Socié; Noël Milpied
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

8.  Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Authors:  Issa F Khouri; Peter McLaughlin; Rima M Saliba; Chitra Hosing; Martin Korbling; Ming S Lee; L Jeffrey Medeiros; Luis Fayad; Felipe Samaniego; Amin Alousi; Paolo Anderlini; Daniel Couriel; Marcos de Lima; Sergio Giralt; Sattva S Neelapu; Naoto T Ueno; Barry I Samuels; Fredrick Hagemeister; Larry W Kwak; Richard E Champlin
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

9.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

Authors:  Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

Authors:  Andrew R Rezvani; Barry Storer; Michael Maris; Mohamed L Sorror; Edward Agura; Richard T Maziarz; James C Wade; Thomas Chauncey; Stephen J Forman; Thoralf Lange; Judith Shizuru; Amelia Langston; Michael A Pulsipher; Brenda M Sandmaier; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2007-12-03       Impact factor: 44.544

View more
  24 in total

1.  Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Authors:  Wichai Chinratanalab; Nishitha Reddy; John P Greer; David Morgan; Brian Engelhardt; Adetola Kassim; Stephen J Brandt; Madan Jagasia; Stacey Goodman; Bipin N Savani
Journal:  Exp Hematol       Date:  2012-01-21       Impact factor: 3.084

2.  Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Authors:  Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-10       Impact factor: 5.742

Review 3.  Allogeneic stem cell transplantation in follicular lymphoma.

Authors:  Issa F Khouri
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

4.  Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.

Authors:  S Yano; T Mori; Y Kanda; J Kato; C Nakaseko; S Fujisawa; N Tomita; R Sakai; K Shono; T Saitoh; N Aotsuka; N Kobayashi; T Saito; S Takahashi; H Kanamori; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2015-07-13       Impact factor: 5.483

5.  Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.

Authors:  Anna Sureda; Mei-Jie Zhang; Peter Dreger; Jeanette Carreras; Timothy Fenske; Herve Finel; Harry Schouten; Silvia Montoto; Stephen Robinson; Sonali M Smith; Ariane Boumedil; Mehdi Hamadani; Marcelo C Pasquini
Journal:  Cancer       Date:  2018-02-09       Impact factor: 6.860

6.  The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Authors:  Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Bone Marrow Transplant       Date:  2020-06-18       Impact factor: 5.483

Review 7.  Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

Authors:  M A Kharfan-Dabaja; N El-Jurdi; E Ayala; A S Kanate; B N Savani; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

8.  Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-09-17       Impact factor: 2.490

9.  Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus M Kröger; Parameswaran N Hari; Kwang Woo Ahn; Jeanette Carreras; Veronika Bachanova; Asad Bashey; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; Mohamed A Kharfan-Dabaja; Andreas Klein; Grace H Ku; Ginna G Laport; Hillard M Lazarus; Alan M Miller; Alberto Mussetti; Richard F Olsson; Shimon Slavin; Saad Z Usmani; Ravi Vij; William A Wood; David G Maloney; Anna M Sureda; Sonali M Smith; Mehdi Hamadani
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-04       Impact factor: 5.742

Review 10.  Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Authors:  Timothy S Fenske; Mehdi Hamadani; Jonathon B Cohen; Luciano J Costa; Brad S Kahl; Andrew M Evens; Paul A Hamlin; Hillard M Lazarus; Effie Petersdorf; Christopher Bredeson
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-27       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.